# Reliable Cardiac biomarkers ST2 Assay Starts with Better Raw Materials > Source: https://www.cnpairbio.com/reliable-cardiac-biomarkers-st2-assay-starts-with-better-raw-materials/ > Author: CNPAIR > Published: 2026-07-14 > Updated: 2026-09-17 sST2 is a soluble cardiac biomarker for heart failure risk stratification, fibrosis, and remodeling. Cnpair provides high-quality ST2 antibodies and antigens validated on chemiluminescence platforms with >98% correlation to leading commercial reagents. ## Key takeaways - sST2 is a soluble cardiac biomarker that reflects myocardial stress, fibrosis, and cardiac remodeling, and it provides prognostic information less affected by age, BMI, renal function, or atrial fibrillation than NT-proBNP. - Cnpair's ST2 antibodies, validated on a chemiluminescence (AE) platform, demonstrated >98% correlation with leading international commercial reagents and are compatible with CLIA, ELISA, and LF platforms. - High-quality ST2 antibodies and antigens are the foundation of reliable ST2 assay development, enabling earlier heart failure detection and more precise clinical evaluation. Heart failure (HF) affects more than 64 million people worldwide and remains one of the leading causes of hospitalization and mortality. Despite advances in treatment, many patients are still diagnosed at advanced stages, making early risk assessment and accurate prognosis increasingly important. One such biomarker is ST2, particularly its soluble form —— sST2. So, what is ST2, and why has it attracted increasing attention as a ST2 cardiac biomarker? ## What Is ST2? ST2, also known as Growth Stimulation Expressed Gene 2 (GDF2), belongs to the interleukin-1 (IL-1) receptor family. The ST2 gene can generate different protein isoforms, with two major forms being ST2L, the membrane-bound form, and sST2 (soluble Growth Stimulation Expressed Gene 2), the soluble form. The biological significance of ST2 is closely related to the IL-33/ST2 signaling pathway. Under normal physiological conditions, IL-33 binds to ST2L on the surface of cardiomyocytes and other cells. This interaction activates protective signaling pathways that can help limit myocardial hypertrophy, fibrosis, and tissue injury.However, when the heart is exposed to excessive mechanical stress, inflammation, or injury, the balance of this pathway can change. Increased cardiac wall stress is associated with increased production and release of sST2. ![](https://www.cnpairbio.com/wp-content/uploads/2026/07/Role-of-IL-33-ST2-axis-on-heart-failure-and-coronary-atherosclerosis-1024x572.png) Unlike ST2L, sST2 is released into the circulation and acts as a decoy receptor for IL-33. By binding IL-33, sST2 can reduce the availability of IL-33 for interaction with membrane-bound ST2L. As a result, the protective IL-33/ST2L signaling pathway may be weakened, potentially contributing to myocardial remodeling and fibrosis. This mechanism makes sST2 particularly interesting as a circulating ST2 marker for cardiovascular disease. ## Clinical Applications of ST2 ### 1. Heart Failure Risk Assessment and Prognosis sST2 is widely studied in heart failure. Elevated levels are linked to myocardial stress, fibrosis, adverse remodeling, and higher risk of cardiovascular mortality, all-cause mortality, heart failure hospitalization, and disease progression. ST2 testing is best used alongside clinical characteristics and other cardiac markers for comprehensive risk stratification. ### 2. Complementary Value to NT-proBNP NT-proBNP is affected by age, obesity, and renal function, while sST2 reflects inflammation, fibrosis, and cardiac remodeling. The two biomarkers provide complementary information. When NT-proBNP is difficult to interpret, adding sST2 can aid risk assessment. Biomarker results should always be interpreted with symptoms, imaging, and medical history. ### 3. Diagnosis and Differential Assessment of Cardiovascular Disease ST2 has been investigated in myocarditis and myocardial infarction, showing potential value in identifying significant myocardial injury or inflammatory conditions. However, ST2 is primarily a complementary biomarker, not a standalone diagnostic test. Its greatest value comes from combining it with ECG, imaging, troponin, and natriuretic peptides. ### 4. Risk Stratification After Acute Cardiovascular Events In acute heart failure and myocardial infarction, elevated sST2 is associated with poorer outcomes. While troponin remains fundamental for detecting myocardial injury, ST2 may provide additional information on remodeling and prognosis, helping identify patients who need closer monitoring. ### 5. Treatment Monitoring and Disease Progression Serial sST2 measurements may reflect changes in myocardial stress and remodeling during treatment. Decreasing levels suggest a favorable trajectory, while persistent or rising levels indicate ongoing risk. ST2 results should not be used in isolation but integrated with symptoms, imaging, NT-proBNP, and troponin. sST2 is a valuable biomarker for assessing myocardial fibrosis, ventricular remodeling, and heart failure prognosis. Unlike traditional biomarkers, it is less affected by age, BMI, renal function, or atrial fibrillation, making it a reliable complement to BNP and NT-proBNP. ## Cardiac biomarkers ST2 Is Recommended by Leading Guidelines sST2 is now recognized independent marker for heart failure risk stratification and long-term prognosis, offering incremental value beyond BNP/NT-proBNP. — [2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure](https://pubmed.ncbi.nlm.nih.gov/35363499/) sST2 is included as a specific biomarker of myocardial fibrosis, and the combined testing of BNP and sST2 is recommended for long-term risk prediction in chronic heart failure. — [2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure](https://www.escardio.org/guidelines/clinical-practice-guidelines/all-esc-practice-guidelines/acute-and-chronic-heart-failure/) **sST2 Concentration Ranges: Clinical Interpretation and Recommended Management** | sST2 Concentration (ng/mL) | Clinical Interpretation | Recommended Management | | --- | --- | --- | | **< 35** | Low risk of myocardial injury | Consider other causes of the disease and discharge from hospital if appropriate. | | **35–70** | Moderate risk of myocardial injury | Diuretic treatment and close monitoring of the patient. | | **> 70** | High risk of myocardial injury, with significant myocardial fibrosis and remodeling | Intensive treatment for heart failure and close follow-up. | As the clinical demand for precision cardiovascular diagnostics continues to grow, developing highly sensitive and reliable ST2 assays begins with one essential factor: high-quality IVD raw materials. ## Cnpair provides raw materials for ST2 cardiac assays. ### Cnpair Cardiac biomarkers ST2 Performance Validated on chemiluminescence (AE) platform, Cnpair's ST2 antibodies demonstrated ＞98% correlation with leading international commercial reagents. Compatible with CLIA, ELISA, and LF, they offer broad flexibility for diverse diagnostic systems and applications. ![](https://www.cnpairbio.com/wp-content/uploads/2026/07/Cnpair-ST2-Antibodies-98-Correlation-Validated-on-Chemiluminescence-Platform.png) At Cnpair, we provide high-quality ST2 antibodies and antigens, to support the development of high-performance diagnostic assays. Our ST2 raw materials deliver high sensitivity, excellent specificity, and consistent batch-to-batch performance, enabling reliable assay development for early heart failure detection and precise clinical evaluation. ## Partner with Cnpair At Cnpair, we provide high-quality IVD raw materials—antibodies, antigens, recombinant proteins, and diagnostic solutions—for accurate, reliable testing across cardiovascular, infectious, oncologic, and autoimmune applications. Whether you're developing a new ST2 assay or optimizing an existing one, our technical team supports you from research to commercialization. Reliable raw materials build reliable diagnostics—enabling earlier detection, better clinical decisions, and improved patient outcomes. ## ST2 FAQ **Can Cnpair provide free ST2 samples?** Yes. Cnpair can provide free ST2 samples for evaluation and assay development. If you are interested, please click here to submit a*[sample request](https://www.cnpairbio.com/contact-us/)*. **How stable are Cnpair's ST2 raw materials?** Cnpair's ST2 raw materials demonstrate good stability under accelerated and storage conditions, supporting consistent performance in assay development and routine testing. Detailed stability data can be provided upon request. **Does Cnpair offer other cardiac biomarker raw materials?** Yes. Cnpair provides a comprehensive portfolio of [*cardiac biomarker raw materials*](https://www.cnpairbio.com/immunoassay-diagnostics/cardiac-markers/) for IVD assay development, including cTnI, cTnT, NT-proBNP, MYO, CK-MB, H-FABP, D-Dimer, and so on. Click here to explore our cardiac biomarker raw materials. **Have Cnpair's ST2 raw materials been successfully applied?** Yes. Cnpair's ST2 raw materials have been successfully applied by multiple IVD reagent companies and have received positive market feedback for their assay performance and application suitability. **What is the ST2 test full form?** ST2 stands for Suppression of Tumorigenicity 2, also known as Growth Stimulation Expressed Gene 2. **What is the sST2 biomarker?** sST2 is the soluble form of ST2 that circulates in the blood. It is mainly studied for heart failure risk stratification and prognosis. **Why is ST2 a cardiac biomarker?** ST2 is associated with myocardial stress, fibrosis, and cardiac remodeling, making it a useful complementary cardiac biomarker. **What is a cardiac marker?** A cardiac marker is a biomarker used to assess myocardial injury, stress, or cardiovascular disease. Common examples include cTnI, NT-proBNP, CK-MB, and ST2. ## Frequently asked questions ### Can Cnpair provide free ST2 samples? Yes. Cnpair can provide free ST2 samples for evaluation and assay development. Contact us. ### How stable are Cnpair's ST2 raw materials? Cnpair's ST2 raw materials demonstrate good stability under accelerated and storage conditions, supporting consistent performance in assay development and routine testing. Detailed stability data can be provided upon request. ### Does Cnpair offer other cardiac biomarker raw materials? Yes. Cnpair provides a comprehensive portfolio of cardiac biomarker raw materials for IVD assay development, including cTnI, cTnT, NT-proBNP, MYO, CK-MB, H-FABP, D-Dimer, and so on. ### Have Cnpair's ST2 raw materials been successfully applied? Yes. Cnpair's ST2 raw materials have been successfully applied by multiple IVD reagent companies and have received positive market feedback for their assay performance and application suitability.